Standout Papers

Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy 1999 2026 2008 2017 1.4k
  1. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy (2002)
    Deborah Grady, David Herrington et al. JAMA
  2. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat (1999)
    Michael Davidson, Jonathan Hauptman et al. JAMA
  3. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Paul M. Ridker, Matt Devalaraja et al. The Lancet

Immediate Impact

11 from Science/Nature 60 standout
Sub-graph 1 of 18

Citing Papers

Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation
2024 Standout
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
2023 Standout

Works of Michael Davidson being referenced

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Michael Davidson 1378 1236 279 2396 117 6.8k
Maria Ida Maiorino 1105 1057 3 3843 175 6.7k
Bu B. Yeap 856 527 20 3870 293 8.5k
Grant D. Huang 509 857 14 2823 94 7.4k
Christopher Patterson 808 914 12 1193 156 7.2k
Jordan D. Tobin 561 1416 4 3206 59 8.2k
Marja­‐Liisa Dahl 2104 473 31 807 148 8.4k
Claudine Legault 589 815 5 1914 75 5.1k
Richard R. Rubin 452 1037 25 6631 94 10.7k
Rachel A. Whitmer 2818 648 10 1623 217 8.8k
Andrew P. Goldberg 857 1549 7 1927 156 9.3k

All Works

Loading papers...

Rankless by CCL
2026